CEPH Message Board - Msg: 1289916

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael R who wrote (122)	4/29/1997 6:04:00 AM
From: harkenman	of 998

Based on WSJ article posted by me on this thread, Rilutek is not a blockbuster drug nor impacts significantly RPR bottom line. Myotrophin even if approved will do the same for CEPH. A drug cocktail will be prohibitively expensive, therefore will have only limited sales based on demographics. Rilutek is the only demonstrated treatment to date for ALS, Myotrophin has been unable to proven that it is safe and effective based on last years review, the european study, May 9 is their 2nd opportunity and based on the streets response well, the stock price is not holding up. <Rilutek may be the only approved drug (for now) - but what good is an approved product if it just isn't going to sell very well? > Does RPR have something in the pipeline that is a lot better? No news has been published to date nor any of their new drugs candidates is targeted for this disease. It is not any of the therapeutic areas targeted by RPR. (Annual Report)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next